Search results
Mar 4, 2020 · Rockville, MD, March 04, 2020 (GLOBE NEWSWIRE) --. MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that Jon Wigginton, M.D., Senior Vice President, Clinical Development & Chief Medical ...
Aug 23, 2022 · Immunotherapy company Bright Peak Therapeutics Inc. nam e d Jon Wigginton as president of R&D. Most recently, Wigginton was senior adviser and chairman of the scientific advisory board of Cullinan Oncology Inc. (NASDAQ:CGEM), having previously been that company’s CMO.
Mar 4, 2020 · MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer ...
Aug 12, 2013 · MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development Dr. Wigginton most recently held dual leadership roles at Bristol-Myers Squibb in clinical development and discovery research of its oncology programs.
Rockville, MD, (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that Jon Wigginton, M.D., Senior Vice President, Clinical Development & Chief Medical Officer, will be ...
2668: 2014: Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer
Mar 4, 2020 · (2020-03-04 | NDAQ:MGNX) MacroGenics Announces Departure of Chief Medical Officer
